30.01.20: Not intended for U.S. and UK Media - Updated results of Phase III trial show:

Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancerFull data to be presented at upcoming scientific meetingmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news